| Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settings. | |
| | |
MedLine Citation:
|
PMID: 16183477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inherently, treating pancreatic adenocarcinoma with chemotherapy is limited by the marginal sensitivity of this tumor to available drugs and drug combinations. For radiotherapy, a similar therapeutic insensitivity is adversely combined with a compromised ability to escalate biologic dose within relevant target volumes because of an intertwining and surrounding matrix of dose-limiting critical normal organs and tissues. The need for effective adjuvant therapy has been intensified by an increase in the safety, applicability, and availability of surgical resection even though such resections remain largely inadequate for producing long-term disease-free survival. The need for improved treatments for locally unresectable tumors remains self-evident based on limited prognosis and the frequency of this presentation. Studies in both domains have attempted to incorporate technical advances in radiotherapy planning and delivery (3-dimensional conformal, intensity modulation) as well as the systemic promise and radiosensitizing properties of gemcitabine-based approaches. The challenges of clinical research are well reflected by the controversies resulting from available studies and the difficulties in successfully designing and executing future trials. |
| | |
Authors:
|
Adam Dickler; Ross A Abrams |
Related Documents
:
|
19885697 - Preoperative diabetes mellitus and long-term survival after resection of pancreatic ade... 20589377 - A phase i study evaluating the role of the anti-epidermal growth factor receptor (egfr)... 20182397 - Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. 10195727 - Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. 21620527 - [resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymp... 18992637 - Methylation status of mgmt gene promoter in meningiomas. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in radiation oncology Volume: 15 ISSN: 1053-4296 ISO Abbreviation: Semin Radiat Oncol Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-09-26 Completed Date: 2006-04-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9202882 Medline TA: Semin Radiat Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 235-44 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612-3804, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
radiotherapy*,
surgery Antineoplastic Combined Chemotherapy Protocols / therapeutic use Chemotherapy, Adjuvant Clinical Trials as Topic Humans Immunotherapy Neoplasm Recurrence, Local Pancreatic Neoplasms / drug therapy*, radiotherapy*, surgery Pancreaticoduodenectomy Radiotherapy, Adjuvant / methods |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
Next Document: Systemic therapy for pancreatic cancer.